| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_36389cdf579846a37f770c664b61f7ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b025939f539692788716c472bbe9b238
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fcffd385b763387b8bc29b364cdd0f54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff8f848ea1c1d88a5c7c3481b6b45515 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C279-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D285-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D271-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C279-16 |
| filingDate |
2015-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d803e3e49e16872f988e5fa3b25a5871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67e9dc3614600391f636168755f9891d |
| publicationDate |
2017-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017298032-A1 |
| titleOfInvention |
Sphingosine kinase inhibitors |
| abstract |
Sphingosine kinases are enzymes that catalyze the biosynthesis of sphingosine-1-phosphate. The invention provides compounds that are effective for inhibition of sphingosine kinase type 1, sphingosine kinase type 2, or both. Certain compounds are selective for sphingosine kinase type 2 relative to sphingosine kinase type 1. Compounds of the invention can be used in treatment of a range of diseases wherein increasing the level of sphingosine-1-phosphate in blood is medically indicated. Diseases that can be treated by administration of an effective dose of a compound of the invention include a neoplastic disease that involves excess vascular growth; macular degeneration or diabetic retinopathy; an allergic disease such as asthma, an inflammatory disease of the eye such as uveitis, scleritis, or vitritis; an inflammatory disease of the kidney; a fibrotic disease; atherosclerosis; or pulmonary arterial hypertension. A compound of the invention can be used to improve the integrity of a vascular barrier in a disease where the vascular barrier is disrupted, such as cancer or Alzheimer's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020101977-A1 |
| priorityDate |
2014-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |